{"database": "openregs", "table": "federal_register", "rows": [["2017-02972", "Bioequivalence Recommendations for Difluprednate; Revised Draft Guidance for Industry; Availability", "Notice", "The Food and Drug Administration (FDA, the Agency, or we) is announcing the availability of a revised draft guidance for industry on generic difluprednate emulsion, entitled \"Draft Guidance on Difluprednate.\" The recommendations provide specific guidance on the design of bioequivalence (BE) studies to support abbreviated new drug applications (ANDAs) for difluprednate emulsion.", "2017-02-15", 2017, 2, "https://www.federalregister.gov/documents/2017/02/15/2017-02972/bioequivalence-recommendations-for-difluprednate-revised-draft-guidance-for-industry-availability", "https://www.govinfo.gov/content/pkg/FR-2017-02-15/pdf/2017-02972.pdf", "Health and Human Services Department; Food and Drug Administration", "221,199", "The Food and Drug Administration (FDA, the Agency, or we) is announcing the availability of a revised draft guidance for industry on generic difluprednate emulsion, entitled \"Draft Guidance on Difluprednate.\" The recommendations provide specific...", null]], "columns": ["document_number", "title", "type", "abstract", "publication_date", "pub_year", "pub_month", "html_url", "pdf_url", "agency_names", "agency_ids", "excerpts", "regulation_id_numbers"], "primary_keys": ["document_number"], "primary_key_values": ["2017-02972"], "units": {}, "query_ms": 7.089316961355507, "source": "Federal Register API & Regulations.gov API", "source_url": "https://www.federalregister.gov/developers/api/v1", "license": "Public Domain (U.S. Government data)", "license_url": "https://www.regulations.gov/faq"}